naltrexone and Coronary Artery Disease

naltrexone has been researched along with Coronary Artery Disease in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jilma, B; Schoergenhofer, C1
Angiolillo, DJ; Bass, TA; Been, L; Faz, G; Franchi, F; Hu, J; Kureti, M; Park, Y; Pineda, AM; Rivas Rios, J; Rollini, F; Soffer, D; Suryadevara, S; Yaranov, D; Zenni, MM1
Cai, W; Li, J; Wang, J; Zhang, Y1

Trials

1 trial(s) available for naltrexone and Coronary Artery Disease

ArticleYear
Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients Treated With Morphine.
    JACC. Cardiovascular interventions, 2019, 08-26, Volume: 12, Issue:16

    Topics: Administration, Intravenous; Administration, Oral; Aged; Analgesics, Opioid; Blood Platelets; Cell Adhesion Molecules; Coronary Artery Disease; Cross-Over Studies; Double-Blind Method; Drug Interactions; Female; Florida; Gastric Emptying; Gastrointestinal Absorption; Humans; Male; Microfilament Proteins; Middle Aged; Morphine; Naltrexone; Narcotic Antagonists; Phosphoproteins; Platelet Aggregation; Platelet Aggregation Inhibitors; Prospective Studies; Quaternary Ammonium Compounds; Ticagrelor; Treatment Outcome

2019

Other Studies

2 other study(ies) available for naltrexone and Coronary Artery Disease

ArticleYear
Methylnaltrexone to Reduce the Inhibitory Effects of Opioids on Drug Absorption.
    JACC. Cardiovascular interventions, 2019, 08-26, Volume: 12, Issue:16

    Topics: Analgesics, Opioid; Coronary Artery Disease; Humans; Morphine; Naltrexone; Quaternary Ammonium Compounds; Ticagrelor; Treatment Outcome

2019
[κ-opioid receptor agonist U50, 488H attenuates myocardial ischemia-reperfusionvia modulating Toll-like receptor 4/nuclear factor-κB signaling in rat].
    Zhonghua xin xue guan bing za zhi, 2014, Volume: 42, Issue:10

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Coronary Artery Disease; Down-Regulation; Heart Conduction System; Myocardial Infarction; Myocardial Ischemia; Myocardium; Naltrexone; NF-kappa B; Rats; Rats, Sprague-Dawley; Receptors, Opioid, kappa; Reperfusion Injury; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha

2014